CAR-T cells, engineered to recognize tumor-associated antigens (TAAs) such as IL13Rα2, HER2, epidermal growth factor receptor (EGFR)/EGFRvIII, and B7-H3, have shown promise in GBM and pediatric brain tumors [129,130]. This evidence concerns the gene ERBB2 and neoplasm.